Drug Profile
Research programme: proteasome inhibitors - Cell Therapeutics
Latest Information Update: 21 Jul 2008
Price :
$50
*
At a glance
- Originator Cell Therapeutics
- Class
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer